Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 28, 2022 08:00 ET | Source: Oncotelic Therapeutics, Inc.

Oncotelic Issues Year End Message to Shareholders

– JV continues to advance to its IPO- OT-101 immunotherapy expanding with at least 10 planned IIS clinical trials for 2023- OT-101 commercialization effort expanding on multiple fronts - Manufacturing...